TY - JOUR
T1 - Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids
AU - Naraev, Boris G.
AU - Ramirez, Robert A.
AU - Kendi, A. Tuba
AU - Halfdanarson, Thorvardur R.
N1 - Funding Information:
Boris G. Naraev has received consulting fees from Advanced Accelerator Applications, a Novartis Company, Lexicon Pharmaceuticals Inc, and Novocure Inc, outside of the current work. Robert A. Ramirez has received personal fees from Advanced Accelerator Applications, a Novartis Company, and from Novartis Pharmaceuticals Corporation. Thorvardur R. Halfdanarson has received consulting fees from Advanced Accelerator Applications (paid to Mayo Clinic), a Novartis Company, research grants from Ipsen and Thermo Fisher Scientific paid to Mayo Clinic, and personal fees from Lexicon Pharmaceuticals Inc, outside the submitted work. A. Tuba Kendi declares no conflicts of interest.Editorial assistance was provided by Harleigh E. Willmott, PhD, CMPP, and Renée Gordon, PhD, of ApotheCom (Yardley, PA). Financial support for medical editorial assistance was provided by Advanced Accelerator Applications, a Novartis Company.
Publisher Copyright:
© 2019 The Authors
PY - 2019/5
Y1 - 2019/5
N2 - Neuroendocrine neoplasms (NEN) are a family of malignancies of diverse origin, including the lung, gastrointestinal tract, and pancreas. Lung NEN include well differentiated neuroendocrine tumors (NET) classified as typical carcinoids or atypical carcinoids, and poorly differentiated neuroendocrine carcinomas classified as small-cell lung carcinoma or large-cell neuroendocrine carcinoma. According to a recent analysis of a large, population-based registry, approximately one-third of all patients with lung typical/atypical carcinoids have distant metastases at diagnosis, and median survival for these patients is 24 months. At present, only 1 therapy is approved by the US Food and Drug Administration (FDA) for patients with advanced lung typical/atypical carcinoids, everolimus, indicating a clear need for more treatment options in this patient population. Although not yet supported by results from randomized prospective trials, somatostatin analogues are considered an acceptable treatment option for patients with lung typical/atypical carcinoids expressing somatostatin receptors. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE was recently approved by the FDA for the treatment of gastroenteropancreatic NET; however, the role of PRRT in patients with lung typical/atypical carcinoids remains unclear, because they were not included in the pivotal NETTER-1 (Neuroendocrine Tumors Therapy) trial. Herein we provide a comprehensive review of the available clinical evidence for efficacy and safety of PRRT in patients with lung typical/atypical carcinoids. On the basis of the preliminary evidence of efficacy and the consistent safety profile in this patient group, we propose that experienced multidisciplinary NET teams may consider PRRT alongside everolimus as an option for patients with advanced somatostatin receptor-positive lung typical/atypical carcinoids whose disease is progressing during first-line treatment with somatostatin analogues.
AB - Neuroendocrine neoplasms (NEN) are a family of malignancies of diverse origin, including the lung, gastrointestinal tract, and pancreas. Lung NEN include well differentiated neuroendocrine tumors (NET) classified as typical carcinoids or atypical carcinoids, and poorly differentiated neuroendocrine carcinomas classified as small-cell lung carcinoma or large-cell neuroendocrine carcinoma. According to a recent analysis of a large, population-based registry, approximately one-third of all patients with lung typical/atypical carcinoids have distant metastases at diagnosis, and median survival for these patients is 24 months. At present, only 1 therapy is approved by the US Food and Drug Administration (FDA) for patients with advanced lung typical/atypical carcinoids, everolimus, indicating a clear need for more treatment options in this patient population. Although not yet supported by results from randomized prospective trials, somatostatin analogues are considered an acceptable treatment option for patients with lung typical/atypical carcinoids expressing somatostatin receptors. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE was recently approved by the FDA for the treatment of gastroenteropancreatic NET; however, the role of PRRT in patients with lung typical/atypical carcinoids remains unclear, because they were not included in the pivotal NETTER-1 (Neuroendocrine Tumors Therapy) trial. Herein we provide a comprehensive review of the available clinical evidence for efficacy and safety of PRRT in patients with lung typical/atypical carcinoids. On the basis of the preliminary evidence of efficacy and the consistent safety profile in this patient group, we propose that experienced multidisciplinary NET teams may consider PRRT alongside everolimus as an option for patients with advanced somatostatin receptor-positive lung typical/atypical carcinoids whose disease is progressing during first-line treatment with somatostatin analogues.
KW - 177Lu-DOTATATE
KW - Atypical carcinoids
KW - Lung neuroendocrine tumors
KW - PRRT
KW - Typical carcinoids
UR - http://www.scopus.com/inward/record.url?scp=85063261961&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063261961&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2019.02.007
DO - 10.1016/j.cllc.2019.02.007
M3 - Review article
C2 - 30910575
AN - SCOPUS:85063261961
SN - 1525-7304
VL - 20
SP - e376-e392
JO - Clinical lung cancer
JF - Clinical lung cancer
IS - 3
ER -